Response to: Zoledronate Increases Bone Mineral Density in Nonambulant Children With Cerebral Palsy: A Randomized, Controlled Trial

J Clin Endocrinol Metab. 2023 Dec 21;109(1):e418-e419. doi: 10.1210/clinem/dgad386.

Authors

Anne Trinh^{1

2

3}, Frances Milat^{1

2

3}

Affiliations

¹ Department of Endocrinology, Monash Health, Melbourne 3168, Australia.
² Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Monash University, Melbourne 3168, Australia.
³ Department of Medicine, School of Clinical Sciences, Monash University, Melbourne 3168, Australia.

PMID: 37437090
DOI: 10.1210/clinem/dgad386

No abstract available

Keywords: cerebral palsy; osteoporosis; pediatric; zoledronic acid.

Publication types

Editorial
Comment

MeSH terms

Bone Density
Bone Density Conservation Agents* / pharmacology
Bone Density Conservation Agents* / therapeutic use
Cerebral Palsy* / drug therapy
Child
Diphosphonates
Humans
Zoledronic Acid

Substances

Zoledronic Acid
Diphosphonates
Bone Density Conservation Agents